Anavex Life Sciences Corp. (AVXL) stock
AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.72−0.02 (-2.78%)
Close on Nov 18, 2026Market cap $66.69MP/E –Yield –
Earnings
Anavex Life Sciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 24, 2026
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
$0.08
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Anavex Life Sciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Sep 30, 2026 | Nov 24, 2026Expected | – | – | – | – |
| Q3 FY2026ended Jun 30, 2026 | Aug 25, 2026before the open | – | – | $0.08 | Release |
| Q1 FY2026ended Dec 31, 2025 | Feb 9, 2026before the open | – | – | -$0.06 | Release |
| Q4 FY2025ended Sep 30, 2025 | Nov 25, 2025before the open | – | – | -$0.11 | Release |
| Q2 FY2024ended Mar 31, 2024 | May 9, 2024before the open | – | – | -$0.13 | Release |
| Q4 FY2020ended Sep 30, 2020 | Dec 28, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Anavex Life Sciences has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Anavex Life Sciences puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Anavex Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- Results
- Update
- Update
- Update
- Update
- Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business UpdateResults
- News
- News
- Update
- Results
- Results
- News
See a number that looks wrong?